SEC Form 4 · accession 0001127602-15-029500

HAEMONETICS CORP · HAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP and Chief Legal Officer

Period of report

Oct 20, 2015

Accepted (ET)

Oct 23, 2015 · 5:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000313143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 20, 2015	A	3,323	$0.01	A	17,971	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-qualified Stock Option (Right to Buy)^F2	$31.97	Oct 20, 2015	A	14,608	A	Oct 20, 2016	Oct 20, 2022	Common Stock	14,608	14,608	D
Performance Shares^F3	$0.00	Oct 20, 2015	A	6,646	A	Sep 30, 2018	Dec 31, 2018	Common Stock	6,646	6,646	D

F1Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
F3Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Standard & Poors Health Care Equipment Index. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2015 and September 30, 2018. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).